AU2002246737B2 - Specific human antibodies for selective cancer therapy - Google Patents

Specific human antibodies for selective cancer therapy Download PDF

Info

Publication number
AU2002246737B2
AU2002246737B2 AU2002246737A AU2002246737A AU2002246737B2 AU 2002246737 B2 AU2002246737 B2 AU 2002246737B2 AU 2002246737 A AU2002246737 A AU 2002246737A AU 2002246737 A AU2002246737 A AU 2002246737A AU 2002246737 B2 AU2002246737 B2 AU 2002246737B2
Authority
AU
Australia
Prior art keywords
cells
binding
scfv
cell
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002246737A
Other languages
English (en)
Other versions
AU2002246737A1 (en
Inventor
Rachel Guy
Yocheved Hagai
Janette Lazarovits
Avigdor Levanon
Orly Lipschitz
Tuvia Peretz
Daniel Plaksin
Esther Szanton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of AU2002246737A1 publication Critical patent/AU2002246737A1/en
Assigned to SAVIENT PHARMACEUTICALS, INC. reassignment SAVIENT PHARMACEUTICALS, INC. Amend patent request/document other than specification (104) Assignors: BIO-TECHNOLOGY GENERAL CORP.
Application granted granted Critical
Publication of AU2002246737B2 publication Critical patent/AU2002246737B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2002246737A 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy Ceased AU2002246737B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29
PCT/US2001/049440 WO2002059264A2 (fr) 2000-12-29 2001-12-31 Anticorps humains specifiques pour la therapie selective du cancer

Publications (2)

Publication Number Publication Date
AU2002246737A1 AU2002246737A1 (en) 2003-02-06
AU2002246737B2 true AU2002246737B2 (en) 2007-03-01

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002246737A Ceased AU2002246737B2 (en) 2000-12-29 2001-12-31 Specific human antibodies for selective cancer therapy

Country Status (15)

Country Link
EP (1) EP1353937A4 (fr)
JP (1) JP2004524023A (fr)
KR (1) KR20030091952A (fr)
CN (1) CN100374456C (fr)
AU (1) AU2002246737B2 (fr)
BR (1) BR0116763A (fr)
CA (1) CA2433227A1 (fr)
CZ (1) CZ20031983A3 (fr)
HU (1) HUP0400775A2 (fr)
IL (1) IL156690A0 (fr)
MX (1) MXPA03005944A (fr)
NZ (1) NZ527173A (fr)
PL (1) PL365758A1 (fr)
RU (1) RU2316564C2 (fr)
WO (1) WO2002059264A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (fr) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions et procedes pour traitement therapeutique
RU2006102571A (ru) * 2003-06-30 2007-08-20 Био-Текнолоджи Дженерал(Израиль) Лтд. (IL) Специфические антитела человека
EP2444421A1 (fr) 2005-04-26 2012-04-25 Pfizer Inc. Anticorps de la P-Cadherine
US8580267B2 (en) 2008-12-19 2013-11-12 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
NZ604805A (en) * 2010-07-09 2014-09-26 Affibody Ab Polypeptides
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
KR102023289B1 (ko) * 2014-10-23 2019-09-19 싱 몰레큘러 메디신, 엘엘씨 세포내 항원에 대해 지향된 단일 도메인 항체
US20160176983A1 (en) * 2014-12-17 2016-06-23 Intrexon Corporation Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
AU2016329542C1 (en) * 2015-10-01 2023-11-23 Fondazione Centro San Raffaele TCR and uses thereof
WO2017087789A1 (fr) * 2015-11-19 2017-05-26 Revitope Limited Complémentation de fragment d'anticorps fonctionnel pour un système à deux composants pour la destruction redirigée de cellules indésirables
KR102505681B1 (ko) * 2016-09-14 2023-03-06 테네오바이오, 인코포레이티드 Cd3 결합 항체
EP4244251A1 (fr) * 2020-11-13 2023-09-20 Prometheus Biosciences, Inc. Méthodes, systèmes et kits pour le traitement d'une maladie inflammatoire ciblant tl1a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6156321A (en) * 1997-01-22 2000-12-05 Board Of Regents, The University Of Texas System Tissue factor methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
NZ527173A (en) 2006-03-31
MXPA03005944A (es) 2005-04-29
BR0116763A (pt) 2004-03-09
CA2433227A1 (fr) 2002-08-01
JP2004524023A (ja) 2004-08-12
KR20030091952A (ko) 2003-12-03
RU2316564C2 (ru) 2008-02-10
IL156690A0 (en) 2004-01-04
CZ20031983A3 (cs) 2005-07-13
EP1353937A4 (fr) 2005-04-13
EP1353937A2 (fr) 2003-10-22
CN100374456C (zh) 2008-03-12
HUP0400775A2 (en) 2007-05-02
WO2002059264A3 (fr) 2003-03-06
PL365758A1 (en) 2005-01-10
RU2003123100A (ru) 2005-03-10
CN1551886A (zh) 2004-12-01
WO2002059264A2 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
US20070149768A1 (en) Specific human antibodies for selective cancer therapy
AU2001249760B2 (en) Mucin-1 specific binding members and methods of use thereof
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20090220486A1 (en) Antibodies and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
JP2005503756A (ja) 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用
JP2005503756A5 (fr)
US20040202665A1 (en) Compositions and methods for therapeutic treatment
CA2491363A1 (fr) Anticorps et leurs applications
US20110117602A1 (en) Human antibody capable of inducing apoptosis
JP2007528711A (ja) 抗体及びその使用
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
US20040208877A1 (en) Antibodies and uses thereof
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: SAVIENT PHARMACEUTICALS, INC.

Free format text: FORMER NAME: BIO-TECHNOLOGY GENERAL CORP.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired